|

CHM-2101 CAR-T cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Chimeric Therapeutics1

Indications

  • Neuroendocrine Tumors1
  • Colorectal Cancer1
  • Gastric Cancer1
  • Cancer1

Atlanta, Georgia1 trial

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Emory University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.